We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App





Less-Sensitive COVID-19 Tests Could Still Achieve Optimal Results If Enough People Are Tested

By LabMedica International staff writers
Posted on 27 Jul 2021
A computational analysis of COVID-19 tests suggests that, in order to minimize the number of infections in a population, the amount of testing matters more than the sensitivity of the tests that are used.

Researchers from Ashoka University (Haryana, India) and the National Centre for Biological Sciences TIFR (Bangalore, India) used computational models to conduct simulations of how COVID-19 spreads among a population, given different combinations of tests and the economic tradeoffs between them. More...
Accounting for the movement of people between different locations, they calculated the total number of infections that would occur by the end of a pandemic under each scenario.

Different states in India use different mixes of two main tests for COVID-19: a very sensitive reverse-transcriptase polymerase-chain-reaction (RT-PCR) test and a less sensitive rapid antigen test. Traditional thinking holds that an all-RT-PCR approach will ultimately lead to fewer overall infections. While RT-PCR tests are more sensitive than rapid antigen tests, they are more expensive and do not provide results immediately. Therefore, the precise mix of tests needed to optimize outcomes while accounting for cost constraints has been unclear.

Their analysis suggests that using only rapid antigen tests could achieve similar outcomes, in terms of total infections, as using only RT-PCR tests - as long as the number of people tested is high enough. This suggests that governments in lower and middle-income countries might be able to achieve optimal outcomes by concentrating on ramping up testing using less sensitive tests which provide immediate results, rather than favoring RT-PCR.

The researchers also note that governments should continue to explore different mixes of tests that will yield the biggest reduction in the number of cases. Given that the costs of testing are falling, this mix could also be recalibrated regularly to monitor what makes the most economic sense.

"Tests are continually improving, and the tradeoffs are in favor of rapid testing, even if it is less sensitive," said Gautam Menon of Ashoka University. "Modeling the effects of using different combinations of tests, keeping in mind their relative costs, can suggest specific policy changes that will have a substantial effect on changing the trajectory of the epidemic."

Related Links:
Ashoka University
National Centre for Biological Sciences



Gold Member
Universal Transport Solution
Puritan®UniTranz-RT
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Silver Member
Urine Test Strips
LabStrip U12 mALB/CREA
Homocysteine Quality Control
Liquichek Homocysteine Control
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Original illustration showing how exposure-linked mutation patterns may influence tumor immune visibility (Photo courtesy of Máté Manczinger, HUN-REN Szeged BRC)

Cancer Mutation ‘Fingerprints’ to Improve Prediction of Immunotherapy Response

Cancer cells accumulate thousands of genetic mutations, but not all mutations affect tumors in the same way. Some make cancer cells more visible to the immune system, while others allow tumors to evade... Read more

Industry

view channel
Image: The addition of Biocare’s complementary IHC antibody, reagent and instrument portfolio enhances Agilent’s immunohistochemistry offering (Photo courtesy of Biocare Medical)

Agilent Technologies Acquires Pathology Diagnostics Company Biocare Medical

Agilent Technologies (Santa Clara, CA, USA) has entered into a definitive agreement to acquire Biocare Medical (Pacheco, CA, USA), expanding its pathology portfolio through the addition of highly complementary... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.